Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Until recently, transgenic and knockout models for disease have been limited almost exclusively to mice. Although useful, these models do not always accurately reflect the physiology and pathology of human disease. Now, advances in genetic engineering technology have extended the spectrum of species available beyond mice, enabling the creation of targeted knock-outs and knock-ins in rats, rabbits, and zebrafish, with the prospect of achieving precise gene targeting in larger animals, including livestock and nonhuman primates.
Life Science researchers are now presented with an unprecedented opportunity to choose the model system that will best reflect the biology or human disease state being studied. During this Webinar, three expert guests will discuss cutting edge genetic engineering technologies and the opportunities to develop more relevant translational animal models beyond knockout mice.
Webinar viewers will:
learn about current state-of-the-art genetic engineering methodologies
obtain an overview of new animal models for research
gain insight into the future direction of transgenic animals that have greater translational value for ADMET and disorders related to the metabolic, immune, cardiovascular, and central nervous systems
have questions answered live by the panel of experts.
Participants:
Carl Lupica, Ph.D.
National Institutes of Health
Baltimore, MD
Rosalba Sacca, Ph.D.
Pfizer, Inc.
Groton, CT
Kerry Ressler, M.D./Ph.D.
Yerkes National Primate Research Center
Atlanta, GA
Quantitative polymerase chain reaction (qPCR) has emerged as a powerful tool in molecular biology laboratories, both in research and in diagnostic settings. Even as qPCR grows in popularity, it is being recognized that there are some challenges associated with the technology, particularly with respect to reproducibility within and between laboratories. Fortunately, many of these limitations can be addressed through a standardized set of best practices. Using the recently published MIQE guidelines as a foundation, our expert panel will address the best practices of qPCR, with the goal of providing researchers with more consistent and reliable data.
During the webinar, the panelists will:
provide an overview of the MIQE guidelines
address qPCR applications and primary challenges
outline best practices and assay design to get the best out of your qPCR
describe the essential quality control steps, including nucleic acid quantification
answer your questions during the live Q&A session.
Participants:
Stephen A. Bustin, Ph.D.
Queen Mary, University of London
London, UK
Gregory L. Shipley, Ph.D.
University of Texas Health Science Center at Houston
Houston, TX
Manju R. Sethi
Thermo Fisher Scientific
Wilmington, DE
